Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Cash from Financing Activities data on record, last reported at $147000.0 in Q3 2022.

  • For Q3 2022, Cash from Financing Activities fell 81.51% year-over-year to $147000.0; the TTM value through Dec 2022 reached $370000.0, down 74.74%, while the annual FY2025 figure was -$25.7 million, 9742.32% down from the prior year.
  • Cash from Financing Activities reached $147000.0 in Q3 2022 per AVIR's latest filing, down from $223000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $426.2 million in Q4 2020 and bottomed at -$913000.0 in Q3 2020.
  • Average Cash from Financing Activities over 3 years is $53.4 million, with a median of $185000.0 recorded in 2022.
  • The widest YoY moves for Cash from Financing Activities: up 7950.0% in 2021, down 99.97% in 2021.
  • A 3-year view of Cash from Financing Activities shows it stood at $426.2 million in 2020, then tumbled by 99.97% to $142000.0 in 2021, then rose by 3.52% to $147000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $147000.0 in Q3 2022, $223000.0 in Q1 2022, and $142000.0 in Q4 2021.